Cell-mediated immunity in human brucellosis

Microbes and Infection

Volumn 13, Issue 2, 2011, Pages 134-142

  Skendros, Panagiotis ^a   Pappas, Georgios ^b   Boura, Panagiota ^c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Institute of Continuing Medical Education of Ioannina   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Brucella; Cellular immunity; Human brucellosis; Immunology

Indexed keywords

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; BRUCELLA; BRUCELLOSIS; CELLULAR IMMUNITY; CLONAL ANERGY; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NONHUMAN; PHAGOCYTOSIS; PHAGOLYSOSOME; PRIORITY JOURNAL; SHORT SURVEY; TH1 CELL;

ANTIGEN-PRESENTING CELLS; BRUCELLA; BRUCELLOSIS; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; MACROPHAGES;

BRUCELLA;

EID: 78651497294     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2010.10.015     Document Type: Short Survey

References (86)

1. Pappas G., Akritidis N., Bosilkovski M., Tsianos E. Brucellosis. N. Engl. J. Med. 2005, 352:2325-2336.
2. Pappas G., Panagopoulou P., Christou L., Akritidis N. Brucella as a biological weapon. Cell. Mol. Life Sci. 2006, 63:2229-2236.
3. Bouza E., Sánchez-Carrillo C., Hernangómez S., González M.J. Spanish Co-operative Group for the study of laboratory-acquired brucellosis: a Spanish national survey. J. Hosp. Infect. 2005, 61:80-83.
4. Skendros P., Boura P., Kamaria F., Raptopoulou-Gigi M. CD80/CD28 co-stimulation in human brucellosis. Clin. Exp. Immunol. 2006, 146:400-408.
5. Golding B., Scott D.E., Scharf O., Huang L.Y., Zaitseva M., Lapham C., Eller N., Golding H. Immunity and protection against Brucella abortus. Microbes Infect. 2001, 3:43-48.
6. Baldwin C.L., Goenka R. Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection?. Crit. Rev. Immunol. 2006, 26:407-442.
7. Gorvel J.P. Brucella: a Mr " Hide" converted into Dr Jekyll. Microbes Infect. 2008, 10:1010-1013.
8. Yingst S., Hoover D.L. T cell immunity to brucellosis. Crit. Rev. Microbiol. 2003, 29:313-331.
9. Jimenez de Bagues M.P., Dudal S., Dornand J., Gross A. Cellular bioterrorism: how Brucella corrupts macrophage physiology to promote invasion and proliferation. Clin. Immunol. 2005, 114:227-238.
10. Gross A., Bertholet S., Mauel J., Dornand J. Impairment of Brucella growth in human macrophagic cells that produce nitric oxide. Microb. Pathog. 2004, 36:75-82.
11. Zaitseva M., King L.R., Manischewitz J., Dougan M., Stevan L., Golding H., Golding B. Human peripheral blood T cells, monocytes, and macrophages secrete macrophage inflammatory proteins 1alpha and 1beta following stimulation with heat-inactivated Brucella abortus. Infect. Immun. 2001, 69:3817-3826.
12. Rittig M.G., Kaufmann A., Robins A., Shaw B., Sprenger H., Gemsa D., Foulongne V., Rouot B., Dornand J. Smooth and rough lipopolysaccharide phenotypes of Brucella induce different intracellular trafficking and cytokine/chemokine release in human monocytes. J. Leukoc. Biol. 2003, 74:1045-1055.
13. Caron E., Gross A., Liautard J.P., Dornand J. Brucella species release a specific, protease-sensitive, inhibitor of TNF-alpha expression, active on human macrophage-like cells. J. Immunol. 1996, 156:2885-2893.
14. Papagoras C.E., Argyropoulou M.I., Voulgari P.V., Vrabie I., Zikou A.K., Drosos A.A. A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab. Clin. Exp. Rheumatol. 2009, 27:124-127.
15. Vrioni G., Pappas G., Priavali E., Gartzonika C., Levidiotou S. An eternal microbe: Brucella DNA load persists for years after clinical cure. Clin. Infect. Dis. 2008, 46:e131-136.
16. Rittig M.G., Alvarez-Martinez M.T., Porte F., Liautard J.P., Rouot B. Intracellular survival of Brucella spp. in human monocytes involves conventional uptake but special phagosomes. Infect. Immun. 2001, 69:3995-4006.
17. Bellaire B.H., Roop R.M., Cardelli J.A. Opsonized virulent Brucella abortus replicates within nonacidic, endoplasmic reticulum-negative, LAMP-1-positive phagosomes in human monocytes. Infect. Immun. 2005, 73:3702-3713.
18. Boschiroli M.L., Ouahrani-Bettache S., Foulongne V., Michaux-Charachon S., Bourg G., Allardet-Servent A., Cazevieille C., Liautard J.P., Ramuz M., O'Callaghan D. The Brucella suis virB operon is induced intracellularly in macrophages. Proc. Natl. Acad. Sci. U S A 2002, 99:1544-1549.
19. Lavigne J.P., Patey G., Sangari F.J., Bourg G., Ramuz M., O'Callaghan D., Michaux-Charachon S. Identification of a new virulence factor, BvfA, in Brucella suis. Infect. Immun. 2005, 73:5524-5529.
20. Cardoso P.G., Macedo G.C., Azevedo V., Oliveira S.C. Brucella spp noncanonical LPS: structure, biosynthesis, and interaction with host immune system. Microb. Cell Fact. 2006, 5:13.
21. Fernandez-Prada C.M., Zelazowska E.B., Nikolich M., Hadfield T.L., Roop R.M., Robertson G.L., Hoover D.L. Interactions between Brucella melitensis and human phagocytes: bacterial surface O Polysaccharide inhibits phagocytosis, bacterial killing, and subsequent host cell apoptosis. Infect. Immun. 2003, 71:2110-2119.
22. Fernandez-Prada C.M., Nikolich M., Vemulapalli R., Sriranganathan N., Boyle S.M., Schurig G.G., Hadfield T.L., Hoover D.L. Deletion of wboA enhances activation of the lectin pathway of complement in Brucella abortus and Brucella melitensis. Infect. Immun. 2001, 69:4407-4416.
23. Kariminia A., Kavoossy G., Khatami S., Zowghi E., Ardestani S.K. Study of interleukin-10 and interleukin-12 productions in response to lipopolysaccharides extracted from two different Brucella strains. Comp. Immunol. Microbiol. Infect. Dis. 2002, 25:85-93.
24. Giambartolomei G.H., Zwerdling A., Cassataro J., Bruno L., Fossati C.A., Philipp M.T. Lipoproteins, not lipopolysaccharide, are the key mediators of the proinflammatory response elicited by heat-killed Brucella abortus. J. Immunol. 2004, 173:4635-4642.
25. Jubier-Maurin V., Boigegrain R.A., Cloeckaert A., Gross A., Alvarez-Martinez M.T., Terraza A., Liautard J., Köhler S., Rouot B., Dornand J., Liautard J.P. Major outer membrane protein Omp25 of Brucella suis is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages. Infect. Immun. 2001, 69:4823-4830.
26. Barrionuevo P., Cassataro J., Delpino M.V., Zwerdling A., Pasquevich K.A., García Samartino C., Wallach J.C., Fossati C.A., Giambartolomei G.H. Brucella abortus inhibits major histocompatibility complex class II expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2. Infect. Immun. 2008, 76:250-262.
27. Radhakrishnan G.K., Yu Q., Harms J.S., Splitter G.A. Brucella TIR Domain-containing protein mimics properties of the toll-like receptor adaptor protein TIRAP. J. Biol. Chem. 2009, 284:9892-9898.
28. Sengupta D., Koblansky A., Gaines J., Brown T., West A.P., Zhang D., Nishikawa T., Park S.G., Roop R.M., Ghosh S. Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL. J. Immunol. 2010, 184:956-964.
29. Bouhet S., Lafont V., Billard E., Gross A., Dornand J. The IFN gamma-induced STAT1-CBP/P300 association, required for a normal response to the cytokine, is disrupted in Brucella-infected macrophages. Microb. Pathog. 2009, 46:88-97.
30. Gross A., Bouaboula M., Casellas P., Liautard J.P., Dornand J. Subversion and utilization of the host cell cyclic adenosine 5'-monophosphate/protein kinase A pathway by Brucella during macrophage infection. J. Immunol. 2003, 170:5607-5614.
31. Billard E., Dornand J., Gross A. Interaction of Brucella suis and Brucella abortus rough strains with human dendritic cells. Infect. Immun. 2007, 75:5916-5923.
32. Billard E., Dornand J., Gross A. Brucella suis prevents human dendritic cell maturation and antigen presentation through regulation of tumor necrosis factor alpha secretion. Infect. Immun. 2007, 75:4980-4989.
33. Zwerdling A., Delpino M.V., Barrionuevo P., Cassataro J., Pasquevich K.A., García Samartino C., Fossati C.A., Giambartolomei G.H. Brucella lipoproteins mimic dendritic cell maturation induced by Brucella abortus. Microbes Infect. 2008, 10:1346-1354.
34. Billard E., Dornand J., Gross A. VirB type IV secretory system does not contribute to Brucella suis' avoidance of human dendritic cell maturation. FEMS Immunol. Med. Microbiol. 2008, 53:404-412.
35. Ocon P., Reguera J.M., Morata P., Juarez C., Alonso A., Colmenero J.D. Phagocytic cell function in active brucellosis. Infect. Immun. 1994, 62:910-914.
36. Rodríguez-Zapata M., Matías M.J., Prieto A., Jonde M.A., Monserrat J., Sánchez L., Reyes E., De la Hera A., Alvarez-Mon M. Human brucellosis is characterized by an intense Th1 profile associated to a defective monocyte function. Infect. Immun. 2010, 78:3272-3279.
37. Karabulut A.B., Sonmez E., Bayindir Y. Effect of the treatment of brucellosis on leukocyte superoxide dismutase activity and plasma nitric oxide level. Ann. Clin. Biochem. 2005, 42:130-132.
38. Boura P., Raptopoulou-Gigi M., Goulis G. Peripheral blood monocyte phagocytosis in patients with chronic brucellosis. J. Immunopharmacol. 1982-1983, 4:377-381.
39. Boura P., Tsapas G., Papadopoulou A., Magoula I., Kountouras G. Monocyte locomotion in anergic chronic brucellosis patients: the in vivo effect of ascorbic acid. Immunopharmacol. Immunotoxicol. 1989, 11:119-129.
40. Lagra F., Raptopoulou-Gigi M., Orphanou-Koumerkeridou H., Goulis G. In vitro effect of interferon alpha-2b on T lymphocyte transformation and leukocyte migration inhibition in patients with chronic brucellosis. Immunopharmacol. Immunotoxicol. 1989, 11:223-232.
41. Printzis S., Raptopoulou-Gigi M., Orphanou-Koumerkeridou H., Lagre F., Goulis G. Immunotherapy in chronic brucellosis. Effect of levamisole and interferon; mechanisms of action and clinical value. Immunopharmacol. Immunotoxicol. 1994, 16:679-693.
42. Boura P., Tsapas G., Kountouras J., Zaharioudaki E. Interferon-A 2a administration in chronic anergic brucellosis. Hepatogastroenterology 1995, 42:919-922.
43. Boura P., Skendros P., Kountouras J., Zacharioudaki E., Tsapas T. Effect of bacterial extracts on the immunologic profile in chronic relapsing brucellosis patients. Int. J. Immunopathol. Pharmacol. 1999, 12:103-111.
44. Tolomeo M., Di Carlo P., Abbadessa V., Titone L., Miceli S., Barbusca E., Cannizzo G., Mancuso S., Arista S., Scarlata F. Monocyte and lymphocyte apoptosis resistance in acute and chronic brucellosis and its possible implications in clinical management. Clin. Infect. Dis. 2003, 36:1533-1538.
45. Renoux M., Renoux G. Brucellosis, immunodepression, and levamisole. Lancet 1977, 1:372.
46. Thornes R.D. Acquired immune suppression in chronic brucellosis. Ir. Med. J. 1983, 76:225.
47. Moreno-Lafont M.C., Lopez-Santiago R., Zumaran-Cuellar E., Paredes-Cervantes V., López-Merino A., Estrada-Aguilera A., Santos-Argumedo L. Antigen-specific activation and proliferation of CD4+ and CD8+ T lymphocytes from brucellosis patients. Trans. R. Soc. Trop. Med. Hyg. 2002, 96:340-347.
48. Skendros P., Boura P., Chrisagis D., Raptopoulou-Gigi M. Diminished percentage of CD4+ T-lymphocytes expressing interleukine-2 receptor alpha in chronic brucellosis. J. Infect. 2007, 54:192-197.
49. Giambartolomei G.H., Delpino M.V., Cahanovich M.E., Wallach J.C., Baldi P.C., Velikovsky C.A., Fossati C.A. Diminished production of T helper 1 cytokines correlates with T cell unresponsiveness to Brucella cytoplasmic proteins in chronic human brucellosis. J. Infect. Dis. 2002, 186:252-259.
50. Rafiei A., Ardestani S.K., Kariminia A., Keyhani A., Mohraz M., Amirkhani A. Dominant Th1 cytokine production in early onset of human brucellosis followed by switching towards Th2 along prolongation of disease. J. Infect. 2006, 53:315-324.
51. Elfaki M.G., Al-Hokail A.A. Transforming growth factor beta production correlates with depressed lymphocytes function in humans with chronic brucellosis. Microbes Infect. 2009, 11:1089-1096.
52. Kinikli S., Turkcapar N., Kucukay M.B., Keskin G., Kinikli G. In vitro nonspecific mitogenic response of T-cell subsets in acute and chronic brucellosis. Diagn. Microbiol. Infect. Dis. 2005, 52:229-233.
53. Skendros P., Sarantopoulos A., Tselios K., Boura P. Chronic brucellosis patients retain low frequency of CD4+ T-lymphocytes expressing CD25 and CD28 after Escherichia coli LPS stimulation of PHA-cultured PBMCs. Clin. Dev. Immunol. 2008, 327346.
54. Demirdag K., Ozden M., Kalkan A., Godekmerdan A., Sirri Kilic S. Serum cytokine levels in patients with acute brucellosis and their relation to the traditional inflammatory markers. FEMS Immunol. Med. Microbiol. 2003, 39:149-153.
55. Akbulut H.H., Kilic S.S., Bulut V., Ozden M. Determination of intracellular cytokines produced by Th1 and Th2 cells using flow cytometry in patients with brucellosis. FEMS Immunol. Med. Microbiol. 2005, 45:253-258.
56. Dornand J., Lafont V., Oliaro J., Terraza A., Castaneda-Roldan E., Liautard J.P. Impairment of intramacrophagic Brucella suis multiplication by human natural killer cells through a contact-dependent mechanism. Infect. Immun. 2004, 72:2303-2311.
57. Dudal S., Turriere C., Bessoles S., Fontes P., Sanchez F., Liautard J., Liautard J.P., Lafont V. Release of LL-37 by activated human Vgamma9Vdelta2 T cells: a microbicidal weapon against Brucella suis. J. Immunol. 2006, 177:5533-5539.
58. Bessoles S., Dudal S., Besra G.S., Sanchez F., Lafont V. Human CD4+ invariant NKT cells are involved in antibacterial immunity against Brucella suis through CD1d-dependent but CD4-independent mechanisms. Eur. J. Immunol. 2009, 39:1025-1035.
59. Kilic S.S., Akbulut H.H., Ozden M., Bulut V. Gamma/delta T cells in patients with acute brucellosis. Clin. Exp. Med. 2009, 9:101-104.
60. Salmerón I., Rodríguez-Zapata M., Salmerón O., Manzano L., Vaquer S., Alvarez-Mon M. Impaired activity of natural killer cells in patients with acute brucellosis. Clin. Infect. Dis. 1992, 15:764-770.
61. Caballero A., Bravo M.J., Nieto A., Colmenero J.D., Alonso A., Martin J. TNFA promoter polymorphism and susceptibility to brucellosis. Clin. Exp. Immunol. 2000, 121:480-483.
62. Skendros P., Boura P., Tsantas N., Debre P., Theodorou I. Frequency analysis of the CCR5delta32 mutation in patients with brucellosis. Scand. J. Infect. Dis. 2002, 34:944-946.
63. Orozco G., Sánchez E., López-Nevot M.A., Caballero A., Bravo M.J., Morata P., de Dios Colmenero J., Alonso A., Martín J. Inducible nitric oxide synthase promoter polymorphism in human brucellosis. Microbes Infect. 2003, 5:1165-1169.
64. Bravo M.J., de Dios Colmenero J., Alonso A., Caballero A. Polymorphisms of the interferon gamma and interleukin 10 genes in human brucellosis. Eur. J. Immunogenet. 2003, 30:433-435.
65. Bravo M.J., de Dios Colmenero J., Alonso A., Caballero A. HLA-B*39 allele confers susceptibility to osteoarticular complications in human brucellosis. J. Rheumatol. 2003, 30:1051-1053.
66. Bravo M.J., de D.Colmenero J., Martín J., Alonso A., Caballero González A. Variation in the NRAMP1 gene does not affect susceptibility or protection in human brucellosis. Microbes Infect. 2006, 8:154-156.
67. Rezazadeh M., Hajilooi M., Rafiei A., Haidari M., Nikoopour E., Kerammat F., Mamani M., Ranjbar M., Hashemi H. TLR4 polymorphism in Iranian patients with brucellosis. J. Infect. 2006, 53:206-210.
68. Rezazadeh M., Hajilooi M., Haidari M., Rafiei A., Alavi S.A., Keramat F. Association of susceptibility to brucellosis and interleukin-4 promoter polymorphism. Scand. J. Infect. Dis. 2006, 38:1045-1049.
69. Haidari M., Hajilooi M., Rezazadeh M., Rafiei A., Alavi S.A., Keramat F. Polymorphism in the promoter region of the CD14 gene and susceptibility to Brucellosis. Immunol. Invest. 2006, 35:239-245.
70. Rafiei A., Hajilooi M., Shakib R.J., Shams S., Sheikh N. Association between the Phe206Leu polymorphism of L-selectin and brucellosis. J. Med. Microbiol. 2006, 55:511-516.
71. Hajilooi M., Rafiei A., Reza Zadeh M., Tajik N. Association of interleukin-1 receptor antagonist gene polymorphism and susceptibility to human brucellosis. Tissue Antigens 2006, 68:331-334.
72. Davoudi S., Amirzargar A.A., Hajiabdolbaghi M., Rasoolinejad M., Soodbakhsh A., Jafari S., Piri H., Maleknejad P., Bagherian H., Madadi N., Nikbin B. Th-1 cytokines gene polymorphism in human brucellosis. Int. J. Immunogenet. 2006, 33:355-359.
73. Rafiei A., Hajilooi M., Shakib R.J., Alavi S.A. Transforming growth factor-beta1 polymorphisms in patients with brucellosis: an association between codon 10 and 25 polymorphisms and brucellosis. Clin. Microbiol. Infect. 2007, 13:97-100.
74. Budak F., Göral G., Heper Y., Yilmaz E., Aymak F., Baştürk B., Töre O., Ener B., Oral H.B. IL-10 and IL-6 gene polymorphisms as potential host susceptibility factors in Brucellosis. Cytokine 2007, 38:32-36.
75. Rasouli M., Kiany S. Association of interferon-gamma and interleukin-4 gene polymorphisms with susceptibility to brucellosis in Iranian patients. Cytokine 2007, 38:49-53.
76. Bravo M.J., Colmenero J.D., Martín J., Alonso A., Caballero A. Polymorphism of the transmembrane region of the MICA gene and human brucellosis. Tissue Antigens 2007, 69:358-360.
77. Rafiei A., Hajilooi M., Vahedi M., Shakib R.J. The Ser128Arg polymorphism for E-selectin gene and brucellosis. Infect. Genet. Evol. 2007, 7:494-498.
78. Hashemi S.H., Hajilooi M., Mamani M., Jamal-Omidi S. Fc gamma receptor IIa polymorphism in patients with brucellosis. Jpn. J. Infect. Dis. 2007, 60:196-197.
79. Rasouli M., Kiany S., Behbin M. Interleukin-10 gene polymorphisms and susceptibility to brucellosis in Iranian patients. Iran J. Immunol. 2008, 5:131-135.
80. Bravo M.J., Colmenero J.D., Queipo-Ortuño M.I., Alonso A., Caballero A. TGF-beta1 and IL-6 gene polymorphism in Spanish brucellosis patients. Cytokine 2008, 44:18-21.
81. Karaoglan I., Pehlivan S., Namiduru M., Pehlivan M., Kilinçarslan C., Balkan Y., Baydar I. TNF-alpha, TGF-beta, IL-10, IL-6 and IFN-gamma gene polymorphisms as risk factors for brucellosis. New Microbiol. 2009, 32:173-178.
82. Bravo M.J., Colmenero J.D., Queipo-Ortuño M.I., Morata P., Orozco G., Martin J., Alonso A., Caballero A. PTPN22 C1858T polymorphism and human brucellosis. Scand. J. Infect. Dis. 2009, 41:109-112.
83. Bravo M.J., Colmenero J.D., Queipo-Ortuño M.I., Martín J., Lavado R., Alonso A., Caballero A. No association of TAP and LMP genetic polymorphism in human brucellosis and its complications. Hum. Immunol. 2010, 71:708-711.
84. Raptopoulou-Gigi M., Boura P., Valcanos N., Goulis G. Conventional therapy and levamisole in the management of chronic brucellosis. J. Infect. Dis. 1983, 147:1123-1124.
85. Irmak H., Buzgan T., Karahocagil M.K., Evirgen O., Akdeniz H., Demiröz A.P. The effect of levamisole combined with the classical treatment in chronic brucellosis. Tohoku J. Exp. Med. 2003, 201:221-228.
86. Dizer U., Hayat L., Beker C.M., Görenek L., Ozgüven V., Pahsa A. The effect of the doxycycline-rifampicin and levamisole combination on lymphocyte subgroups and functions of phagocytic cells in patients with chronic brucellosis. Chemotherapy 2005, 51:27-31.